CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03899792
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:42.272508+00:00
Published At: 2026-01-06T00:00:00+00:00
Record Updated At: 2026-01-06
Results Posted At: 2026-01-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Medullary Thyroid Cancer", "Infantile Myofibromatosis", "Infantile Fibrosarcoma", "Papillary Thyroid Cancer", "Soft Tissue Sarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-06"
protocolSection.identificationModule.nctId: "NCT03899792"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-01-06"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.